Affairs of the Heart: Innovation in Cardiovascular Research and Development

Clinical Pharmacology and Therapeutics

Volumn 102, Issue 2, 2017, Pages 162-168

  Honig, P ^a   Terzic, A ^b  

^a Mayo Clinic ^*  (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATRIAL FIBRILLATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR SYSTEM; CLINICAL DEVELOPMENT PLAN; CLINICAL RESEARCH; EDITORIAL; HEALTH CARE SYSTEM; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HOSPITAL SERVICE; HUMAN; MORBIDITY; PRIORITY JOURNAL; WORLD HEALTH ORGANIZATION; CARDIOVASCULAR DISEASES; DRUG APPROVAL; DRUG DEVELOPMENT; DRUG INDUSTRY; EXPERIMENTAL THERAPY; PROCEDURES; RESEARCH; TRENDS;

CARDIOVASCULAR DISEASES; DRUG APPROVAL; DRUG DISCOVERY; DRUG INDUSTRY; HUMANS; RESEARCH; THERAPIES, INVESTIGATIONAL;

EID: 85024379270     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1002/cpt.737     Document Type: Editorial

References (34)

1. World Health Organization. Non-communicable diseases: 2017 Update. . Accessed 1 May 2017.
2. Terzic, A. & Waldman, S. Chronic diseases: the emerging pandemic. Clin. Transl. Sci. 4, 225–226 (2011).
3. Benjamin, E.J. et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association. Circulation. 135, e146–e603 (2017).
4. Global Burden of Disease Mortality and Causes of Death Collaborators. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 388, 1459–1544 (2016).
5. Waldman, S.A. & Terzic, A. Cardiovascular health: the global challenge. Clin. Pharmacol. Ther. 90, 483–485 (2011).
6. Braunwald, E. The ten advances that have defined modern cardiology. Trends Cardiovasc. Med. 24, 179–183 (2014).
7. Jessup, M. The heart failure paradox: an epidemic of scientific success. Circulation 129, 2717–2722 (2014).
8. Terzic, A., Pfenning, M.A., Gores, G.J. & Harper, C.M. Jr. Regenerative medicine build-out. Stem Cells Transl. Med. 4, 1373–1379 (2015).
9. Honig, P. & Huang, S. Intelligent pharmaceuticals: Beyond the tipping point. Clin. Pharmacol. Ther. 95, 455–459 (2014).
10. Honig, P.K. Pharmacotherapy for neurodegenerative diseases: are we approaching a tipping point? Clin. Pharmacol. Ther. 98, 452–455 (2015).
11. FDA new drug approvals . Accessed 10 April 2017
12. Hwang, T.J., Franklin, J.M. & Kesselheim, A.S. Effect of US Food and Drug Administration's cardiovascular safety guidance on diabetes drug development. Clin. Pharmacol. Ther. 102, 290–296 (2017).
13. Ringel, M.S. et al. Occlusion in the flow of new drugs for cardiovascular disease. Clin. Pharmacol. Ther. 102, 246–253 (2017).
14. Meyer, R.J. Commentary on R&D trends away from general medicine/cardiovascular drugs: Can the FDA help reverse the trend? Clin. Pharmacol. Ther. 102, 186–188 (2017).
15. Waldman, S.A. & Terzic, A. Bioinnovation enterprise: an engine driving breakthrough therapies. Clin. Pharmacol. Ther. 99, 8–13 (2016).
16. Barghash, M.H. & Desai, A.S. First-in-class composite angiotensin receptor–neprilysin inhibitors (ARNi) in practice. Clin. Pharmacol. Ther. 102, 265–268 (2017).
17. Waldman, S.A. & Terzic, A. Molecular insights provide the critical path to disease mitigation. Clin. Pharmacol. Ther. 95, 3–7 (2014).
18. Nanayakkara, S. & Kaye, D.M. Targets for heart failure with preserved ejection fraction. Clin. Pharmacol. Ther. 102, 228–237 (2017).
19. Arora, R. Gene therapy for atrial fibrillation in heart failure. Clin. Pharmacol. Ther. 102, 200–202 (2017).
20. Terzic, A. & Behfar, A. Regenerative medicine in the practice of cardiology. Eur. Heart J. 37, 1089–1090 (2016).
21. Fujita, B., Zimmermann, W-Hubertus. Engineered heart repair. Clin. Pharmacol. Ther. 102, 197–199 (2017).
22. Shaheen, N., Shiti, A. & Gepstein, L. Pluripotent cell-based platforms in cardiac disease modeling and drug testing. Clin. Pharmacol. Ther. 102, 203–208 (2017).
23. Papadimitriou, L. & Butler, J. “Fast Track” development and approval process for heart failure therapeutics. Clin. Pharmacol. Ther. 102, 184–186 (2017).
24. Prescott, J.S. et al. Evaluation of therapeutics for advanced stage heart failure and other severely-debilitating or life-threatening diseases. Clin. Pharmacol. Ther. 102, 219–227 (2017).
25. Gattis Stough, W. & Patterson, J.H. Role and value of clinical pharmacy in heart failure management. Clin. Pharmacol. Ther. 102, 209–212 (2017).
26. Motiejunaite, J., Chouihed, T. & Mebazaa, A. Upcoming challenges in multidisciplinary heart failure management: Active role of future clinical pharmacists. Clin. Pharmacol. Ther. 102, 180–182 (2017).
27. Chakkera, H.A., Sharif, A. & Kaplan, B. Negative cardiovascular consequences of small molecule immunosuppressants. Clin. Pharmacol. Ther. 102, 269–276 (2017).
28. Piano, M.R. Cannabis smoking and cardiovascular health: it's complicated. Clin. Pharmacol. Ther. 102, 191–193 (2017).
29. Master, Z., Fu, W., Paciulli, D. & Sipp, D. Industry responsibilities in tackling direct-to-consumer marketing of unproven stem cell treatments. Clin. Pharmacol. Ther. 102, 177–179 (2017).
30. Caraballo, P.J., Bielinski, S.J., St. Sauver, J.L. & Weinshilboum, R.M. Electronic medical record-integrated pharmacogenomics and related clinical decision support concepts. Clin. Pharmacol. Ther. 102, 254–264 (2017).
31. Clinical Development Success Rates 2006-2015. . Accessed 10 April 2017.
32. FDA Science and Mission at Risk. Report of the US FDA Science Board. . Accessed 10 April 2017.
33. Mission Possible: How FDA can move at the speed of science. . Accessed 10 April 2017.
34. st Century Cures. . Accessed 10 April 2017.